Status:

UNKNOWN

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Lead Sponsor:

Sohail Rao

Conditions:

Covid19

Eligibility:

All Genders

12+ years

Phase:

PHASE2

Brief Summary

No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate t...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing
  • 12 years of age and older weighing at least 40 kg
  • are at ":high risk" for progressing to severe COVID-19 and/or hospitalization
  • High risk is defined as patients who meet at least one of the following criteria:
  • Have a body mass index (BMI) \>35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are over 65 years of age
  • Are over 55 years of age AND have: cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease
  • Are 12 - 17 years of age AND have
  • BMI \>85th percentile for their age and gender based on CDC o growth charts, ii. sickle cell disease OR iii. congenital or acquired heart disease OR iv. neurodevelopmental disorders, for example, cerebral palsy, OR a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
  • v. asthma, reactive airway or other chronic respiratory disease o that requires daily medication for control.
  • Exclusion Criteria
  • Younger than 12 years of age
  • Do not meet criteria to be classified as "high risk'

Exclusion

    Key Trial Info

    Start Date :

    November 20 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    January 31 2023

    Estimated Enrollment :

    1000 Patients enrolled

    Trial Details

    Trial ID

    NCT04840459

    Start Date

    November 20 2020

    End Date

    January 31 2023

    Last Update

    March 29 2022

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    DHR Health Institute for Research and Development

    Edinburg, Texas, United States, 78539

    2

    DHR Health

    Edinburg, Texas, United States, 78539

    3

    Starr County Memorial Hospital

    Rio Grande City, Texas, United States, 78582